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Middle  East respiratory  syndrome  coronavirus  (MERS-CoV),  an  emerging  infectious  disease  of  growing
global  importance,  has  caused  severe  acute  respiratory  disease  in  more  than  1600  people,  resulting  in
more than  600  deaths.  The  high  case  fatality  rate, growing  geographic  distribution  and  vaguely  deﬁnedeywords:
iddle East Respiratory Syndrome
oronavirus
accine
esearch
evelopment
epidemiology  of  MERS-CoV  have  created  an  urgent  need for effective  public  health  countermeasures,
paramount  of  which  is  an  effective  means  of prevention  through  a  vaccine  or antibody  prophylaxis.
Despite  the relatively  few  number  of  cases  to-date,  research  and  development  of MERS-CoV  vaccine
candidates  is advancing  quickly.  This  review  surveys  the  landscape  of  these  efforts  across  multiple  groups
in  academia,  government  and  industry.
© 2016  World  Health  Organization;  licensee  Elsevier  Ltd.  This  is  an open  access  article  under  the  CC. Introduction
Middle East Respiratory Syndrome (MERS-CoV) was ﬁrst iso-
ated in September 2012 from a patient in Saudi Arabia who
resented two months earlier with severe acute respiratory infec-
ion and acute renal failure [1]. Retrospective testing of samples
n Jordan identiﬁed earlier cases from a nosocomial outbreak in
pril 2012 [2]. Although the majority of MERS-CoV cases (∼75%)
ave occurred in Saudi Arabia, 25 other countries have conﬁrmed
mported or autochthonously transmitted cases (Fig. 1) [3,4]. The
ost recent and largest outbreak outside of Saudi Arabia occurred
n South Korea in May  2015 [5], raising concern for an eruption
f regional outbreaks or accelerated global spread, similar to the
hylogenetically related severe acute respiratory syndrome coro-
avirus (SARS-CoV) that killed nearly a thousand people a decade
arlier [6]. Although the deﬁnitive host for MERS-CoV has not
et been established, closely related coronaviruses have been iso-
ated from bats across wide geographic areas [7–9]. Mounting
vidence has strongly implicated dromedary camels as the inter-
ediate animal reservoir, as serological surveys throughout the
iddle East and North Africa have demonstrated them to have a
igh prevalence of MERS-CoV binding or neutralizing Abs [10–13].
dditionally, outbreak investigations have suggested epidemio-
ogic linkage between farm camels and human cases [14].
MERS-CoV is a spherical, enveloped, single-stranded, positive
ense RNA beta-coronavirus [1,15]. Its genome contains a replicase
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locus at the 5′ end and codes for structural proteins toward the
3′ end. The most immunogenic of the viral proteins is Spike (S), a
trimeric, envelope-anchored, type I fusion glycoprotein that inter-
faces with its human host cognate receptor, dipeptidyl peptidase 4
(DPP4), to mediate viral entry [16,17]. S comprises two subunits:
S1, which contains the receptor-binding domain and determines
cell tropism; and S2, the location of the cell fusion machinery.
Although DPP4 has a broad tissue distribution, most of the clinical
manifestations of MERS-CoV can be attributed to its localization to
the lower respiratory tract [18,19]. Much like other coronaviruses,
MERS-CoV can also cause signiﬁcant dysfunction of the gastroin-
testinal, cardiovascular, renal, and neurologic systems. MERS-CoV
is distinct, though, in its tendency to cause greatest harm to older
individuals with concurrent comorbidities of one or more of these
organ-systems [20,21].
Despite past efforts to develop coronavirus countermeasures
in response to the SARS-CoV pandemic, there are currently no
prophylactic or therapeutic interventions of proven efﬁcacy for
MERS-CoV or any other coronavirus infection. Although com-
bination treatment with ribavirin and interferons were shown
to improve clinical outcomes in MERS-CoV-infected non-human
primates (NHPs), treatment was  initiated very soon after viral chal-
lenge (∼8 h) and results have not been replicated in humans [22].
In fact, no experimental interventions have demonstrated appre-
ciable beneﬁt in acutely ill patients in a consistent or controlled
manner. Rapidly scaled treatments based on naturally occurring
neutralizing antibodies such as convalescent plasma or hyperim-
mune globulin, on the other hand, have demonstrated mortality
reductions for other respiratory infections and may  hold promise
ss article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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Fig. 1. Geographic distribution (MERS-CoV) conﬁrmed cases, 2012–2016. To date, there have been more than 1600 cases and 600 deaths from MERS-CoV. Shading corresponds
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or MERS-CoV as well [23]. Their development, however, is limited
y logistical challenges, local technical capacity, and donor supply.
upportive management, adapted from guidelines developed for
ARS-CoV, has thus far been the mainstay of MERS-CoV treatment.
. Prospective for an effective human vaccine
The global will to develop a coronavirus vaccine faded in the
ftermath of SARS-CoV pandemic but has since gained renewed
omentum in the face of the current MERS-CoV outbreak. Previous
pproaches to coronavirus vaccine development were broad and
ncluded whole-inactivated and live-attenuated viruses, recombi-
ant vectors and protein subunits, as well as DNA and RNA based
latforms [6]. Most developers based their immunogen designs
n the S surface glycoprotein, the primary target for neutralizing
ntibodies during any natural coronavirus infection. A number of
reclinical and clinical studies showed that the SARS-CoV S1 pro-
ein subunit, and speciﬁcally the RBD at its core, could serve as a
ominant target for neutralizing antibodies in mice, non-human
rimates, and humans [24]. S1, therefore, became the basis for a
umber of promising SARS-CoV vaccine candidates.
The S1 protein subunit and RBD have also been the basis for
everal MERS-CoV vaccine candidates (Fig. 2) [25–29]. Resolu-
ion of RBD crystal structures alone or in complex with the DPP4
eceptor [25,30,31] have informed the design of immunogens that
ave been expressed either as recombinant protein fragments or
onjugates to the fragment crystallizable (Fc) region of human anti-
odies. Both types of constructs, in formulation with aluminum
alt or oil-in-water adjuvants, have elicited neutralizing antibod-
es of high potency across multiple viral strains. Despite their
emonstrated immunogenicity in animal models and anticipated
afety in humans, RBD or S1-subunit based vaccine candidates are
imited in their epitope breadth. Although the coronavirus genomes
re not as variable as other RNA viruses, the RBD is the mostr of cases conﬁrmed in 2016. The number of cases before 2016 are not reﬂected in
mutable region, containing mutation sites that deﬁne antibody
escape variants [25,32]. Thus, vaccine candidates that elicit a more
diverse antibody repertoire as well as a robust cellular immune
response may  offer the advantage of broader and more durable
protection.
Full-length S used as an immunogen could at least increase the
breadth of the antibody response; however, it has been difﬁcult
to express, and may  require additional work to produce a stable
soluble trimer of the S ectodomain. Investigators at the University
of Maryland, in collaboration with Novavax, Inc., have overcome
this problem through the development of S rosettes that are sta-
ble and immunogenic in murine models [33]. Vaccines that mimic
natural infection, such as live-attenuated viruses or recombinant
viral vectors, may  elicit even more robust immunity. Live attenu-
ated viruses have historically been among the most immunogenic
platforms available, as they have the capacity to present multiple
antigens across the viral life cycle in their native conformations.
Although a live-attenuated MERS-CoV has yet to be tested, one
has been constructed and has the potential to be protective [34].
However, manufacturing live-attenuated viruses requires contain-
ment in a biosafety level 3 or 4 facility. Additionally, live-attenuated
viruses carry the hazards of inadequate attenuation or reversion
to wild type form and causing disseminated disease, particularly
in immunocompromised hosts. Given that moderately immuno-
compromised adults with co-morbidities such as diabetes mellitus
and chronic kidney disease have suffered the most severe MERS-
CoV disease, these individuals may  comprise a target population
for immunization, thus making a live-attenuated virus vaccine
a less viable option. Replication competent viral vectors could
pose a similar threat for disseminated disease in the immuno-
suppressed. Replication deﬁcient vectors, however, avoid that risk
while maintaining the advantages of native antigen presentation,
elicitation of T cell immunity and the ability to express multi-
ple antigens. To date, two recombinant vector platforms—modiﬁed
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Fig. 2. Summary of active MERS-CoV vaccine candidates in development. Currently, there are more than a dozen published active vaccine candidates across ﬁve general
platforms in development for MERS-CoV. To date, all but one of the candidates are in various stages of preclinical development. The DNA-alone candidate has entered Phase
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accinia virus Ankara (MVA) and adenovirus vectors—have been
sed to express MERS-CoV S glycoprotein. Both viral vec-
ors have been immunogenic and one of the MVA  candidates
as protective in a mouse model transduced with human DPP4
35–38].
Although replication deﬁcient vectors are relatively safe and
mmunogenic, their ability to deliver genetic material for expres-
ion could be impeded by pre-existing or developing immunity to
he vector itself. One way to overcome this limitation is by admin-
stering different vectors in a so-called prime-boost immunization
egimen. As this strategy has been effective for other pathogens, it is
ikely that the same success could be recapitulated for MERS-CoV.
he use of more than one type of platform or antigen in a single
accine also increases the likelihood of inducing a broad repertoire
f antibodies with diverse mechanisms of viral neutralization. One
accine regimen developed at the US National Institutes of Health
s based on full-length S DNA and a truncated S1 subunit glycopro-
ein and has elicited neutralizing antibodies in mice directed at both
he S1—within and outside the RBD—and S2 subunits. Immuniza-
ion with these constructs also protected NHPs from severe lung
isease after intra-tracheal challenge with MERS-CoV [25]. A DNA-
nly vaccine, expressing multiple antigens, has also been developed
y Inovio Pharmaceuticals and GeneOne Life Science Inc. and has
een advanced to a Phase I ﬁrst-in-human trial.
. Monoclonal antibodies (mAbs) in developmentEach of the vaccine candidates that have been mentioned is
eing developed for prophylactic use. However, as the total number
f cases (>1600) [3,4] and reproductive rate (∼0.7) of MERS-
oV are both relatively low [39], it will be difﬁcult to deﬁne theBD: receptor binding domain of the Spike glycoprotein; Ad5: adenovirus serotype
target populations for vaccination that would support the invest-
ment in manufacturing and advanced product development. Also,
with such low incidence and lack of robust animal models, it would
be difﬁcult to achieve a vaccine efﬁcacy result that would be sufﬁ-
cient to support licensure. Human mAbs, on the other hand, could
be used without as much discrimination in an outbreak setting
for post-exposure prophylaxis and early treatment. The advan-
tages of mAbs over polyclonal antibodies (administered through
convalescent plasma or hyperimmune globulin) are their higher
potency, greater speciﬁcity, more extensive pre-licensing evalua-
tion and consequently improved safety proﬁle. Additionally, mAbs
can help deﬁne immunogenic epitopes through crystallographic
analysis, thereby providing atomic level detail for the design of bet-
ter immunogens. However, the timeline for mAb  development may
be longer and potentially cost more than some vaccines.
Despite requirements for greater upfront investment, several
groups have developed highly potent mAbs that are currently
being advanced through pre-clinical stages of testing (Fig. 3). Some
have been isolated from immunized animals (mice/humanized
mice/NHPs) [25,40], while others have been identiﬁed from either
an antibody human phage library [41–44] or memory B cells of
infected and recovered human survivors [45]. Almost all of the
mAbs that have been reported target the Spike RBD. It is likely that
mAbs directed at other sites on the Spike glycoprotein have been
recovered but are not as potent neutralizers. Most of those that have
been published bind to recombinant Spike with picomolar afﬁnity
and neutralize MERS-CoV pseudovirus at a half maximal inhibitory
concentration (IC50) of 0.1 mcg/l or less. Additionally, some have
demonstrated protective efﬁcacy in pre- and post-exposure pro-
phylaxis animal models [44,45]. The successes thus far in isolating
potent and protective mAbs may  prove useful for therapeutic devel-
opment where the target population is well deﬁned. It may  prove
K. Modjarrad / Vaccine 34 (2016) 2982–2987 2985
Fig. 3. Summary of MERS-CoV monoclonal antibodies (mAbs) in development.
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ore challenging to advancing these products to licensure and full-
cale production at affordable costs for the purpose of prophylaxis
n as of yet undeﬁned populations.
. Target populations for vaccination
The vaguely deﬁned epidemiology of MERS-CoV has compli-
ated the design and implementation of appropriate public health
ountermeasures. Most transmission events have occurred either
n the setting of household clusters or nosocomial outbreaks
46–51]. It is also likely that the virus has been introduced multiple
imes into human populations from a large zoonotic reservoir, i.e.
romedary camels. Given the broad distribution and ownership of
amels in the Arabian Peninsula where most cases have occurred, a
argeted vaccine campaign may  prove difﬁcult. As the outbreak in
he Republic of Korea revealed, patients and workers in the same
ealthcare facility as an infected patient are at high risk for sec-
ndary acquisition. An optimal strategy may  be to use vaccines in
onjunction with stringent infection control practices in hospitals
here MERS-CoV cases are being treated.
The epidemiologic link of MERS-CoV between bats, camels,
nd humans presents an opportunity for a veterinary vaccine to
nterrupt the transmission cycle. A successful precedent for this
o-called “OneHealth” approach toward mitigating human disease
ith a veterinary vaccine exists in the example of Equivac®, a
endra virus vaccine developed solely for horses [52]. Although
endra virus is even more rare than MERS-CoV, it is highly fatal
ith no treatment other than intensive supportive management.
n 2012, a protein subunit vaccine was licensed and rolled-out
n Australia, where all outbreaks of the virus occurred. Since that
ime, the incidence in horses has fallen precipitously and no human
ases have been detected [53]. A similar strategy may  be applica-
le to MERS-CoV; however, a veterinary vaccination in this context
ould be deployed solely for the sake of protecting humans, as the
irus causes only mild upper respiratory illness in camels. Safety
nd reduction in viral shedding would have to be demonstrated
n immunization, challenge and transmission studies of camel or
amelid populations, one of which has shown efﬁcacy [54].utralization against MERS-CoV and in some cases have protected transgenic mice
nding Domain; S: Spike glycoprotein; S1: Spike domain containing RBD; S2: Spike
5. Knowledge gaps and ways forward
One of the primary challenges to developing countermea-
sures to MERS-CoV is the lack of an appropriate animal model
that recapitulates the natural history of human disease. Much
of the difﬁculty originates from the absence of the virus’s cog-
nate DPP4 receptor. One group approached this problem by
successfully transducing mice with an adenoviral vector express-
ing human DPP4 [55]. Although more relevant than a standard
murine model, transient transduction of the desired protein may
result in inconsistent tissue expression of adenovirus antigens.
Agrawal et al. made an important advance with the development
of a transgenic mouse model that demonstrated productive, dis-
seminated MERS-CoV infection [56]. Although rhesus macaques
do not manifest full clinical disease, they develop a transient
lower respiratory infection that can be quantiﬁed and evaluated
by computed tomography. Investigators at the NIH Rocky Moun-
tain Laboratories (RML) and Integrated Research Facility (IRF) have
also independently been developing potentially lethal marmoset
models that could be used for the evaluation of vaccines, mAbs and
therapeutics [57].
As MERS-CoV vaccines—both active and passive—are developed
and tested, not only will more relevant animal models be required,
but there will also be a need for a more detailed understanding of
the epidemiology, immunology, and pathogenesis of the virus. In
the aftermath of the West African Ebola virus epidemic and in the
face of the current Zika virus outbreak, the global health commu-
nity has coalesced around the realization that a multi-faceted plan
is required to quickly and efﬁciently respond to global public health
emergencies. The World Health Organization is currently develop-
ing a blueprint by which that preparation and response can follow,
with MERS-CoV highlighted as a case study. Although MERS-CoV
still causes relatively few cases in a limited geographic distribu-
tion, its high case fatality and sudden outbreak in in Korea have
proven it to be a pathogen of public health concern. The concen-
tration of the epidemic to Saudi Arabia also raises the specter of
international spread every year during Hajj, one of the largest mass
gathering events in the world. Ultimately, the development of a
safe and effective vaccine for MERS-CoV may  not yield its greatest
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